Incyte (INCY) Projected to Post Quarterly Earnings on Thursday

Incyte (NASDAQ:INCY) is expected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Incyte to announce earnings of ($3.93) per share and revenue of $1.47 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.94. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the company earned $1.57 EPS. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, analysts expect Incyte to post $1.97 EPS for the current fiscal year and $7.55 EPS for the next fiscal year.

Incyte Price Performance

Shares of INCY stock opened at $116.60 on Wednesday. Incyte has a 12-month low of $84.02 and a 12-month high of $132.60. The firm has a fifty day moving average of $120.99 and a 200-day moving average of $107.96.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on INCY. Barclays upped their target price on shares of Incyte from $134.00 to $139.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Zacks Research cut Incyte from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Piper Sandler lifted their price target on Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Sanford C. Bernstein reissued a “market perform” rating and issued a $104.00 price target on shares of Incyte in a research note on Thursday, August 13th. Finally, Truist Financial boosted their price target on Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, October 14th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $131.43.

Insider Buying and Selling

In other news, EVP Patrick Mayes sold 41,899 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the completion of the transaction, the executive vice president directly owned 61,441 shares of the company’s stock, valued at $7,339,741.86. This trade represents a 40.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 10,801 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the transaction, the insider directly owned 183,200 shares of the company’s stock, valued at $23,002,592. This represents a 5.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 55,342 shares of company stock valued at $6,659,208. Insiders own 16.20% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: New ESMO 2026 data for INCB161734 and INCA33890 advanced Incyte’s gastrointestinal-cancer portfolio. INCB161734 reportedly produced lasting tumor responses in pancreatic cancer, positioning Incyte as a credible competitor in the KRAS G12D treatment race. EMSO 2026: Incyte a firm contender in G12D pancreatic cancer race as early candidate shines
• Positive Sentiment: Incyte said it is “neck and neck” with Revolution Medicines in the KRAS G12D pancreatic-cancer market, suggesting meaningful commercial potential if its candidate continues to demonstrate durable efficacy. ESMO: Why Incyte sees itself neck and neck with RevMed in KRAS G12D pancreatic cancer race
• Positive Sentiment: H.C. Wainwright reiterated its Buy rating and $152 price target, citing the pancreatic-cancer data as evidence that Incyte may be undervalued. Incyte KRAS G12D PDAC data underscore undervalued opportunity
• Positive Sentiment: Incyte and Genmab agreed to evaluate a three-drug combination for first-line KRAS G12D-mutated metastatic colorectal cancer, expanding the potential reach of the companies’ targeted-oncology collaboration. Incyte and Genmab collaborate to develop a new colorectal cancer therapy
• Neutral Sentiment: Morgan Stanley maintained a Hold rating. The firm sees promise in Incyte’s oncology pipeline but believes long-term development execution and program timing risks temper the near-term investment case. Balanced view on Incyte

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.